Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Intravenous Infusions of S-KETAMINE in Fibromyalgia Syndromes: an Exploratory Study.

To see complete record on, please visit this link

Id: NCT04436250

Organisation Name: Grand Hôpital de Charleroi

Overal Status: Recruiting

Start Date: October 10, 2020

Last Update: August 3, 2022

Lead Sponsor: Grand Hôpital de Charleroi

Brief Summary: Fibromyalgia is a cause of chronic pain, classified by the Internal Classification of Diseases (ICD) as a primary chronic pain with specific diagnostic criteria established by the American College of Rheumatology (ACR). No treatment to its complete cure is available at this time, all treatments having as purpose pain relief and an improvement of quality of life by combining pharmacologic and nonpharmacologic treatments. One of the mechanisms proposed in fibromyalgia is the central sensitisation phenomenon, by which the central nervous system becomes "hypersensitive" to nociceptive or non-nociceptive stimuli. The receptor involved in this phenomenon is the N-methyl-D-aspartate receptor to which ketamine binds. Ketamine has therefore been proposed as a co-treatment in chronic pain with central sensitization phenomena, such as fibromyalgia.

  • Fibromyalgia

Total execution time in seconds: 0.29364585876465